Slide 1: Earnings Call Q2 2026
˥ August 18 , 2026 EARNINGS CALL Q 2 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains "forward - looking statements" relating to future events, and Evogene Ltd. ( the “ Company ” ) , may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters rega
Slide 3: Agenda
EARNINGS CALL Q 2 2026 AGENDA • Opening Remarks - By Nir Nimrodi, Evogene ’ s Chairman • CEO Update – By Ofer Haviv • Financial Report Review – By Polina Ravzin • Q&A
Slide 4: Evogene Pioneers Real-World Innovation
EVOGENE PIONEERS REAL - WORLD INNOVATION Using a proprietary generative AI engine, we generate novel and highly potent small molecules, optimized across multiple - parameters, for the pharmaceutical and ag - chemical industries 4
Slide 5: • Established ChemPass AI as our core platform – developing a first -
• Established ChemPass AI as our core platform – developing a first - in - class generative AI foundation model for small molecules and integrating autonomous AI Agents in partnership with Google Cloud. • Validated the commercial value of our technology - secured 6 drug development agreements with
Slide 6: Gen AI Engine
GEN AI ENGINE Growing number of collaborations for a diverse pipeline of drug candidates Proven strategic collaborations driving our ag - chem pipeline PIONEERING IN PHARMA REVOLUTIONIZING AG OUR STORY ChemPass AI - computational engine for the generation & optimization of small molecules
Slide 7: Agenda
EARNINGS CALL Q 2 2026 AGENDA • Opening Remarks - By Nir Nimrodi, Evogene ’ s Chairman • CEO Update – By Ofer Haviv • Financial Report Review – By Polina Ravzin • Q&A
Slide 8: Pharma Division – Drugs / Ag Division – Ag-Chemicals
8 PHARMA DIVISION – DRUGS Demyelination Disorders Neutrophil - Derived Inflammatory Diseases Metabolic Disease Therapy Resistant Lung Cancer Herbicides INTERNAL PIPELINE Wheat Blotch AG DIVISION* – AG - CHEMICALS AG DIVISION ͐ – Operations in this field are conducted through our subsidiary, AgPle
Slide 9: Diversified Drug Discovery Pipeline
DIVERSIFIED DRUG DISCOVERY PIPELINE – (INITIATED Q 4 / 25 ) PARTNER IND PRE - CLINICAL LEAD OPTIMIZATION HIT - TO - LEAD HIT ID PREPROCESSING PROGRAM INDICATION COLLABORATIONS Undisclosed EVG - O 311 Oncology EVG - M 410 Metabolism* EVG - I 110 Immunology EVG - N 210 Neurology EVG - O 310 Oncology
Slide 10: End-to-End Process – Novel, Highly Potent, Optimized Molecule
END - TO - END PROCESS – NOVEL, HIGHLY POTENT, OPTIMIZED MOLECULE HIT SCREENING WITH POINTHIT TM LEAD OPTIMIZATION WITH LEADOP GPT TM Step 1 Step 3 HIT TO LEAD WITH ACTIVESEARCH TM 5 ( 3 %) 164 Step 2 38 ( 23 %) In Vivo Activity 2 ( 0.5 %) 11 ( 2.5 %) Enzymatic Activity 440 Ordered Compounds Ordered
Slide 11: Agents' Integration – Google Cloud Collaboration
BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL AGENTS' INTEGRATION “ This expanded collaboration with Evogene demonstrates the power of integrating cutting - edge artificial intelligence into scientific research . By leveraging our technology to deploy advanced AI agents, we are enabling Evogene
Slide 12: Evogene – Looking Forward
12 PHARMA DIVISION – DRUGS EVOGENE – LOOKING FORWARD AG DIVISION* – AG - CHEMICALS AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus . ADDITIONAL TECH COLLABORATIONS TO MAINTAIN OUR COMPETITIVE ADVANTAGE • Progress in existing pipeline • New collaborations with b
Slide 13: Agenda
EARNINGS CALL Q 2 2026 AGENDA • Opening Remarks - By Nir Nimrodi, Evogene ’ s Chairman • CEO Update – By Ofer Haviv • Financial Report Review – By Polina Ravzin • Q&A
Slide 14: Evogene Subsidiaries' Activity
˥˨ 14 EVOGENE SUBSIDIARIES ’ ACTIVITY
Slide 15: Consolidated Interim Statements of Financial Position
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION U.S. dollars in thousands | Unaudited June 30 , 2026 Dec. 31 , 2025 June 30 , 2026 Dec. 31 , 2025 ASSETS LIABILITIES AND EQUITY Current assets Cash and cash equivalents 9,316 12,956 Restricted cash 35 32 Trade receivables 384 317 Other receivable
Slide 16: Consolidated Interim Statements of Profit or Loss
CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS U.S. dollars in thousands (except share and per share amounts) | Unaudited Six months ended June 30 , Three months ended June 30 , Year ended Dec. 31 , 2026 2025 (*) 2026 2025 (*) 2025 (*) Audited Unaudited Revenues 681 2,877 347 534 3,503 Cost of re
Slide 17: Agenda
EARNINGS CALL Q 2 2026 AGENDA • Opening Remarks - By Nir Nimrodi, Evogene ’ s Chairman • CEO Update – By Ofer Haviv • Financial Report Review – By Polina Ravzin • Q&A
Slide 18: Creating Real-World Innovation for a Better Future
. Creating } REAL-WORLD 4 INNOVATION for a better future